Clinical trial NCT03614715 - References

Healthy — Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a)

Citation(s)

•   Ben-Amor AF, Trochanov A, Fischer TZ
  Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon ß-1a. Adv Ther. 2015 May;32(5):445-54. doi: 10.1007/s12325-015-0212-6. Epub 2015 May 20.
•   Bertolotto A, Deisenhammer F, Gallo P, Sölberg Sørensen P
  Immunogenicity of interferon beta: differences among products. J Neurol. 2004 Jun;251 Suppl 2:II15-II24. Review.
•   Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, Melis F, Giordana MT
  Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods. 2001 Oct 1;256(1-2):141-52.
•   Capalbo M, Palmisano L, Bonino F, Pellas C, Maset J
  Intramuscular natural beta interferon in the treatment of chronic hepatitis B: a multicentre trial. Italian Hepatitis B Study Group. Ital J Gastroenterol. 1994 Jun;26(5):238-41.
•   Casoni F, Merelli E, Bedin R, Sola P, Bertolotto A, Faglioni P
  Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis? Acta Neurol Scand. 2004 Jan;109(1):61-5.
•   Chemello L, Cavalletto L, Noventa F, Bonetti P, Casarin C, Bernardinello E, Pontisso P, Donada C, Casarin P, Belussi F, et al
  Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha. J Viral Hepat. 1995;2(2):91-6.
•   Di Girolamo G, Kauffman MA, González E, Papouchado M, Ramírez A, Keller G, Carbonetto C, Dabsys S, Vidal A, Sterin-Prync A, Diez RA
  Bioequivalence of two subcutaneous pharmaceutical products of interferon beta la. Arzneimittelforschung. 2008;58(4):193-8. doi: 10.1055/s-0031-1296492.
•   Hovanessian AG, Justesen J
  The human 2'-5'oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2'-5' instead of 3'-5' phosphodiester bond formation. Biochimie. 2007 Jun-Jul;89(6-7):779-88. Epub 2007 Feb 20. Review.
•   Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al
  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996 Mar;39(3):285-94. Erratum in: Ann Neurol 1996 Sep;40(3):480.
•   Lengyel P
  Biochemistry of interferons and their actions. Annu Rev Biochem. 1982;51:251-82. Review.
•   Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A
  Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology. 2004 Jun 8;62(11):2031-7.
•   Miles SA, Wang HJ, Cortes E, Carden J, Marcus S, Mitsuyasu RT
  Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections. Ann Intern Med. 1990 Apr 15;112(8):582-9.
•   Munafo A, Trinchard-Lugan I I, Nguyen TX, Buraglio M
  Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol. 1998 Mar;5(2):187-193.
•   Nagai M, Arai T
  Clinical effect of interferon in malignant brain tumours. Neurosurg Rev. 1984;7(1):55-64.
•   Pestka S, Langer JA, Zoon KC, Samuel CE
  Interferons and their actions. Annu Rev Biochem. 1987;56:727-77. Review.
•   Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis
  European Study Group on interferon beta-1b in secondary progressive MS. Lancet. 1998 Nov 7;352(9139):1491-7.
•   PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group
  PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001 Jun 26;56(12):1628-36. Erratum in: Neurology 2001 Sep 25;57(6):1146.
•   Romano A, Sadan Y
  Ten years of experience with human fibroblast interferon in treatment of viral ophthalmic infections. Metab Pediatr Syst Ophthalmol (1985). 1988;11(1-2):43-6.
•   Scagnolari C, Duda P, Bagnato F, De Vito G, Alberelli A, Lavolpe V, Girardi E, Durastanti V, Trojano M, Kappos L, Antonelli G
  Pharmacodynamics of interferon beta in multiple sclerosis patients with or without serum neutralizing antibodies. J Neurol. 2007 May;254(5):597-604. Epub 2007 Apr 10.
•   Williams GJ, Witt PL
  Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX. J Interferon Cytokine Res. 1998 Nov;18(11):967-75.

Comparative Trial of the Pharmacokinetics and Pharmacodynamics of Intramuscularly Injected CinnoVex® and Avonex® in Healthy Volunteers

Details for clinical trial NCT03614715